Endpoints exclusive: Bob Nelsen's Resilience snags Florida CDMO working with the Defense Department on Covid-19 antibody
Resilience has only been in existence for less than six months, but Bob Nelsen’s next-gen manufacturing play has made plenty of moves shortly after debuting with an $800 million launch round. Now, the biotech looking to change drug manufacturing is picking up a Florida CDMO partnered with the Department of Defense on a Covid-19 antibody.
Resilience is acquiring CDMO Ology Bioservices in a deal that will add two manufacturing sites to the bicoastal biotech’s footprint as well as a government-backed monoclonal antibody, a source close to the matter said Monday. Financial terms of the deal were not available.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.